External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms.


Journal

JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861

Informations de publication

Date de publication:
01 10 2020
Historique:
pubmed: 28 8 2020
medline: 4 2 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

A computer algorithm that performs at or above the level of radiologists in mammography screening assessment could improve the effectiveness of breast cancer screening. To perform an external evaluation of 3 commercially available artificial intelligence (AI) computer-aided detection algorithms as independent mammography readers and to assess the screening performance when combined with radiologists. This retrospective case-control study was based on a double-reader population-based mammography screening cohort of women screened at an academic hospital in Stockholm, Sweden, from 2008 to 2015. The study included 8805 women aged 40 to 74 years who underwent mammography screening and who did not have implants or prior breast cancer. The study sample included 739 women who were diagnosed as having breast cancer (positive) and a random sample of 8066 healthy controls (negative for breast cancer). Positive follow-up findings were determined by pathology-verified diagnosis at screening or within 12 months thereafter. Negative follow-up findings were determined by a 2-year cancer-free follow-up. Three AI computer-aided detection algorithms (AI-1, AI-2, and AI-3), sourced from different vendors, yielded a continuous score for the suspicion of cancer in each mammography examination. For a decision of normal or abnormal, the cut point was defined by the mean specificity of the first-reader radiologists (96.6%). The median age of study participants was 60 years (interquartile range, 50-66 years) for 739 women who received a diagnosis of breast cancer and 54 years (interquartile range, 47-63 years) for 8066 healthy controls. The cases positive for cancer comprised 618 (84%) screen detected and 121 (16%) clinically detected within 12 months of the screening examination. The area under the receiver operating curve for cancer detection was 0.956 (95% CI, 0.948-0.965) for AI-1, 0.922 (95% CI, 0.910-0.934) for AI-2, and 0.920 (95% CI, 0.909-0.931) for AI-3. At the specificity of the radiologists, the sensitivities were 81.9% for AI-1, 67.0% for AI-2, 67.4% for AI-3, 77.4% for first-reader radiologist, and 80.1% for second-reader radiologist. Combining AI-1 with first-reader radiologists achieved 88.6% sensitivity at 93.0% specificity (abnormal defined by either of the 2 making an abnormal assessment). No other examined combination of AI algorithms and radiologists surpassed this sensitivity level. To our knowledge, this study is the first independent evaluation of several AI computer-aided detection algorithms for screening mammography. The results of this study indicated that a commercially available AI computer-aided detection algorithm can assess screening mammograms with a sufficient diagnostic performance to be further evaluated as an independent reader in prospective clinical trials. Combining the first readers with the best algorithm identified more cases positive for cancer than combining the first readers with second readers.

Identifiants

pubmed: 32852536
pii: 2769894
doi: 10.1001/jamaoncol.2020.3321
pmc: PMC7453345
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1581-1588

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

Radiology. 2009 Dec;253(3):641-51
pubmed: 19864507
J Am Coll Radiol. 2019 Apr;16(4 Pt A):411-418
pubmed: 30037704
JAMA Oncol. 2016 Jun 1;2(6):737-43
pubmed: 26893205
Eur J Radiol. 2003 Feb;45(2):135-8
pubmed: 12536093
J Natl Cancer Inst. 2004 Dec 15;96(24):1840-50
pubmed: 15601640
JAMA Intern Med. 2015 Nov;175(11):1828-37
pubmed: 26414882
Curr Oncol. 2018 Jun;25(Suppl 1):S115-S124
pubmed: 29910654
Nature. 2020 Jan;577(7788):89-94
pubmed: 31894144
J Natl Cancer Inst. 2019 Sep 1;111(9):916-922
pubmed: 30834436
Eur J Cancer Prev. 2010 Mar;19(2):87-93
pubmed: 20010429
J Digit Imaging. 2020 Apr;33(2):408-413
pubmed: 31520277
Eur Radiol. 2016 Aug;26(8):2520-8
pubmed: 26560729
Expert Rev Med Devices. 2019 May;16(5):351-362
pubmed: 30999781
IEEE Trans Med Imaging. 2020 Apr;39(4):1184-1194
pubmed: 31603772
JAMA Netw Open. 2020 Mar 2;3(3):e200265
pubmed: 32119094
Radiology. 2019 Feb;290(2):305-314
pubmed: 30457482
J Natl Cancer Inst. 2004 Oct 6;96(19):1432-40
pubmed: 15467032
Br J Cancer. 1987 May;55(5):547-51
pubmed: 3606947
Br J Cancer. 1997;75(5):762-6
pubmed: 9043038
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Radiology. 2017 Apr;283(1):49-58
pubmed: 27918707
Br J Cancer. 2013 Jun 11;108(11):2205-40
pubmed: 23744281
Radiology. 2019 Aug;292(2):331-342
pubmed: 31210611

Auteurs

Mattie Salim (M)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Department of Radiology, Karolinska University Hospital, Stockholm, Sweden.

Erik Wåhlin (E)

Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.

Karin Dembrower (K)

Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Department of Radiology, Capio Sankt Görans Hospital, Stockholm, Sweden.

Edward Azavedo (E)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Theodoros Foukakis (T)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Department of Radiology, Karolinska University Hospital, Stockholm, Sweden.

Yue Liu (Y)

Division of Computational Science and Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.

Kevin Smith (K)

KTH Royal Institute of Technology, Science for Life Laboratory, Solna, Sweden.

Martin Eklund (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

Fredrik Strand (F)

Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Breast Radiology, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH